Literature DB >> 9514871

Complex formation of NS5B with NS3 and NS4A proteins of hepatitis C virus.

S Ishido1, T Fujita, H Hotta.   

Abstract

At present, the mechanism of replication of the HCV genome remains unclear. Recently, NS5B and NS3 of HCV have been shown to exhibit RNA-dependent RNA polymerase and helicase activities, respectively, both of which are indispensable for virus RNA replication. In this study, we examined the complex formation of NS5B with NS3 and NS4A, a cofactor for NS3. We show here that NS5B forms a complex with NS3 through an amino-terminal portion of NS3. The NS3-NS5B complex formation took place both in the presence and absence of NS4A. We also demonstrate that NS5B form a complex with NS4A in the absence of NS3. These results suggest that NS3, NS4A and NS5B interact with each other to form a complex that functions as part of the replication machinery of HCV.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9514871     DOI: 10.1006/bbrc.1998.8202

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  41 in total

1.  Mutations that affect dimer formation and helicase activity of the hepatitis C virus helicase.

Authors:  Y L Khu; E Koh; S P Lim; Y H Tan; S Brenner; S G Lim; W J Hong; P Y Goh
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Hepatitis C virus NS3 helicase forms oligomeric structures that exhibit optimal DNA unwinding activity in vitro.

Authors:  Bartek Sikora; Yingfeng Chen; Cheryl F Lichti; Melody K Harrison; Thomas A Jennings; Yong Tang; Alan J Tackett; John B Jordan; Joshua Sakon; Craig E Cameron; Kevin D Raney
Journal:  J Biol Chem       Date:  2008-02-18       Impact factor: 5.157

3.  Hepatitis C virus RNA replication and virus particle assembly require specific dimerization of the NS4A protein transmembrane domain.

Authors:  Andrew Kohlway; Nathan Pirakitikulr; Francisco N Barrera; Olga Potapova; Donald M Engelman; Anna M Pyle; Brett D Lindenbach
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

4.  Modulation of hepatitis C virus genome replication by glycosphingolipids and four-phosphate adaptor protein 2.

Authors:  Irfan Khan; Divya S Katikaneni; Qingxia Han; Lorena Sanchez-Felipe; Kentaro Hanada; Rebecca L Ambrose; Jason M Mackenzie; Kouacou V Konan
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

5.  Determination of Critical Requirements for Classical Swine Fever Virus NS2-3-Independent Virion Formation.

Authors:  D Dubrau; S Schwindt; O Klemens; H Bischoff; N Tautz
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

6.  Specific interaction of hepatitis C virus protease/helicase NS3 with the 3'-terminal sequences of viral positive- and negative-strand RNA.

Authors:  R Banerjee; A Dasgupta
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

7.  The Hepatitis C Virus NS5A Stimulates NS5B During In Vitro RNA Synthesis in a Template Specific Manner.

Authors:  Elizabeth M Quezada; Caroline M Kane
Journal:  Open Biochem J       Date:  2009-04-20

8.  Alpha interferon inhibits hepatitis C virus replication in primary human hepatocytes infected in vitro.

Authors:  Valérie Castet; Chantal Fournier; Alexandre Soulier; Rozenn Brillet; Joliette Coste; Dominique Larrey; Daniel Dhumeaux; Patrick Maurel; Jean-Michel Pawlotsky
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Secondary structure of the 3' terminus of hepatitis C virus minus-strand RNA.

Authors:  Catherine Schuster; Catherine Isel; Isabelle Imbert; Chantal Ehresmann; Roland Marquet; Marie Paule Kieny
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  NS3 helicase from the hepatitis C virus can function as a monomer or oligomer depending on enzyme and substrate concentrations.

Authors:  Thomas A Jennings; Samuel G Mackintosh; Melody K Harrison; Deniz Sikora; Bartek Sikora; Bhuvanesh Dave; Alan J Tackett; Craig E Cameron; Kevin D Raney
Journal:  J Biol Chem       Date:  2008-12-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.